Renaissance Technologies LLC bought a new position in shares of Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB) in the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund bought 66,100 shares of the biotechnology company’s stock, valued at approximately $106,000. Renaissance Technologies LLC owned about 0.35% of Catabasis Pharmaceuticals as of its most recent SEC filing.
A number of equities research analysts have recently weighed in on the company. Oppenheimer Holdings, Inc. dropped their target price on Catabasis Pharmaceuticals from $9.00 to $4.00 and set an “outperform” rating for the company in a research report on Tuesday, August 15th. HC Wainwright boosted their target price on Catabasis Pharmaceuticals from $8.00 to $9.00 and gave the stock a “buy” rating in a research report on Monday, August 14th. Zacks Investment Research downgraded Catabasis Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday, May 19th. Finally, Wedbush restated an “outperform” rating and set a $4.00 target price on shares of Catabasis Pharmaceuticals in a research report on Wednesday, June 21st. Three analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. Catabasis Pharmaceuticals presently has a consensus rating of “Buy” and an average price target of $4.50.
Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB) traded up 0.5536% during midday trading on Friday, reaching $1.6893. The company had a trading volume of 720,338 shares. The company’s market capitalization is $37.98 million. Catabasis Pharmaceuticals, Inc. has a 12-month low of $1.08 and a 12-month high of $7.89. The stock has a 50-day moving average price of $1.51 and a 200 day moving average price of $1.33.
Catabasis Pharmaceuticals (NASDAQ:CATB) last announced its earnings results on Thursday, August 10th. The biotechnology company reported ($0.32) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.40) by $0.08. Equities analysts forecast that Catabasis Pharmaceuticals, Inc. will post ($1.39) EPS for the current year.
About Catabasis Pharmaceuticals
Catabasis Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics based on its Safely Metabolized And Rationally Targeted (SMART), a linker drug discovery platform. The SMART linker drug discovery platform enables to engineer product candidates that can modulate multiple targets in a disease.
Receive News & Ratings for Catabasis Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catabasis Pharmaceuticals Inc. and related companies with our FREE daily email newsletter.